Cyclosporiasis natural history, complications and prognosis

Jump to navigation Jump to search

Cyclosporiasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cyclosporiasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X-Ray

CT Scan

MRI

Ultrasound

Treatment

Medical Therapy

Primary Prevention

Case Studies

Case #1

Cyclosporiasis natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

slides

Images

American Roentgen Ray Society Images of Cyclosporiasis natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cyclosporiasis natural history, complications and prognosis

on Cyclosporiasis natural history, complications and prognosis

Cyclosporiasis natural history, complications and prognosis in the news

Blogs on Cyclosporiasis natural history, complications and prognosis

Directions to Hospitals Treating Cyclosporiasis

Risk calculators and risk factors for Cyclosporiasis natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Joseph Nasr, M.D.[2]; João André Alves Silva, M.D. [3]

Overview

Cyclosporiasis is an intestinal infection caused by the coccidian protozoan parasite Cyclospora cayetanensis. Infection occurs after ingestion of sporulated oocysts in food or water contaminated with feces. The incubation period is typically approximately 7 days, although symptom onset may occur from several days to 2 weeks or longer after exposure.[1][2]

The characteristic manifestation is prolonged or relapsing watery diarrhea. Other manifestations include anorexia, weight loss, nausea, abdominal cramping, bloating, flatulence, fatigue, headache, myalgia, and low-grade fever. Vomiting may occur but is less common.[3][4]

The clinical course varies according to prior exposure, immune status, age, and geographic setting. Infection may be asymptomatic or mild among individuals living in endemic areas, whereas previously unexposed travelers and persons involved in foodborne outbreaks may develop more clinically apparent illness. Disease may be more severe or prolonged in infants, young children, elderly patients, and immunocompromised individuals, including patients with advanced HIV infection and organ transplant recipients.[2][5]

Natural History

Following ingestion, unsporulated oocysts are not immediately infectious to another person. The oocysts must mature and sporulate in the environment before they become infectious. Therefore, direct person-to-person transmission is considered unlikely under ordinary circumstances.[6]

After an incubation period of approximately 1 week, symptomatic patients typically develop watery diarrhea that may be frequent, prolonged, and relapsing.[1][4] Associated gastrointestinal and constitutional manifestations may include:

Without treatment, symptoms may persist for weeks and occasionally months. Diarrhea may temporarily resolve and subsequently recur. Constitutional manifestations, particularly fatigue and myalgia, may continue after the gastrointestinal symptoms have improved.[6][2]

Patients living in endemic areas may have asymptomatic infection or milder, shorter-lasting disease, potentially related to repeated exposure and partial immunity. Previously unexposed travelers from non-endemic regions may experience more pronounced clinical illness.[2][5]

Infants, young children, elderly patients, and immunocompromised individuals may experience more severe or prolonged symptoms. In patients with advanced HIV infection, cyclosporiasis may be chronic or relapsing and may be associated with marked weight loss, malabsorption, and biliary tract involvement.[7][2]

Complications

Complications are uncommon but may occur in patients with severe, prolonged, or inadequately treated disease.

Gastrointestinal and metabolic complications

Prolonged diarrhea and reduced oral intake may result in:

Malabsorption is related to small-intestinal epithelial injury and may contribute to persistent weight loss and nutritional impairment.[8]

Biliary complications

Biliary tract involvement has been reported predominantly in patients with advanced HIV infection. Manifestations may include biliary disease and acalculous cholecystitis.[7][9]

Rare extraintestinal manifestations

Rare extraintestinal manifestations described in the literature include:

These associations are based largely on case reports or small case series and should be considered uncommon complications rather than routine manifestations of cyclosporiasis.[10][11][2]

Prognosis

Cyclosporiasis is generally not life-threatening, particularly in immunocompetent patients. Most patients recover without permanent sequelae, although untreated illness may be prolonged and may follow a relapsing course.[6][2]

Morbidity is primarily related to persistent diarrhea, dehydration, electrolyte abnormalities, weight loss, malabsorption, and prolonged fatigue. Infants, elderly patients, and individuals with impaired immunity are at increased risk of severe or prolonged disease.[2][5]

Patients with advanced HIV infection or other substantial immunosuppression may develop chronic, recurrent, or extraintestinal disease. In these patients, the clinical course may be complicated by severe wasting, malabsorption, or biliary tract involvement.[7]

Prompt diagnosis and appropriate treatment are generally associated with clinical resolution. Persistent or recurrent symptoms should prompt consideration of incomplete treatment, reinfection, continued exposure, immunosuppression, or an alternative gastrointestinal diagnosis.[6]

References

  1. 1.0 1.1 Herwaldt BL, Ackers ML (1997). "An outbreak in 1996 of cyclosporiasis associated with imported raspberries. The Cyclospora Working Group". N Engl J Med. 336 (22): 1548–1556. doi:10.1056/NEJM199705293362202. PMID 9164810.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 Giangaspero A, Gasser RB (2019). "Human cyclosporiasis". Lancet Infect Dis. 19 (7): e226–e236. doi:10.1016/S1473-3099(18)30789-8.
  3. Connor BA, Reidy J, Soave R (1999). "Cyclosporiasis: clinical and histopathologic correlates". Clin Infect Dis. 28 (6): 1216–1222. doi:10.1086/514780. PMID 10451156.
  4. 4.0 4.1 Fleming CA, Caron D, Gunn JE, Barry MA (1998). "A foodborne outbreak of Cyclospora cayetanensis at a wedding: clinical features and risk factors for illness". Arch Intern Med. 158 (10): 1121–1125. PMID 9605784.
  5. 5.0 5.1 5.2 Almeria S, Cinar HN, Dubey JP (2019). "Cyclospora cayetanensis and cyclosporiasis: an update". Microorganisms. 7 (9): 317. doi:10.3390/microorganisms7090317.
  6. 6.0 6.1 6.2 6.3 Centers for Disease Control and Prevention. "Clinical Overview of Cyclosporiasis". Retrieved July 10, 2026.
  7. 7.0 7.1 7.2 Sifuentes-Osornio J, Porras-Cortés G, Bendall RP, Morales-Villarreal F, Reyes-Terán G, Ruiz-Palacios GM (1995). "Cyclospora cayetanensis infection in patients with and without AIDS: biliary disease as another clinical manifestation". Clin Infect Dis. 21 (5): 1092–1097. doi:10.1093/clinids/21.5.1092. PMID 8589126.
  8. Ortega YR, Nagle R, Gilman RH, Watanabe J, Miyagui J, Quispe H; et al. (1997). "Pathologic and clinical findings in patients with cyclosporiasis and a description of intracellular parasite life-cycle stages". J Infect Dis. 176 (6): 1584–1589. PMID 9395371.
  9. de Górgolas M, Fortés J, Fernández Guerrero ML (2001). "Cyclospora cayetanensis cholecystitis in a patient with AIDS". Ann Intern Med. 134 (2): 166. PMID 11177324.
  10. Richardson RF, Remler BF, Katirji B, Murad MH (1998). "Guillain-Barré syndrome after Cyclospora infection". Muscle Nerve. 21 (5): 669–671. PMID 9572253.
  11. Connor BA, Johnson EJ, Soave R (2001). "Reiter syndrome following protracted symptoms of Cyclospora infection". Emerg Infect Dis. 7 (3): 453–454. doi:10.3201/eid0703.010317. PMC 2631790. PMID 11384527.

Template:WH Template:WS